Top

Published in:

Open Access 01-08-2013 | PRECLINICAL STUDIES

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

Authors: S. Betty Yan, Victoria L. Peek, Rose Ajamie, Sean G. Buchanan, Jeremy R. Graff, Steven A. Heidler, Yu-Hua Hui, Karen L. Huss, Bruce W. Konicek, Jason R. Manro, Chuan Shih, Julie A. Stewart, Trent R. Stewart, Stephanie L. Stout, Mark T. Uhlik, Suzane L. Um, Yong Wang, Wenjuan Wu, Lei Yan, Wei J. Yang, Boyu Zhong, Richard A. Walgren

Published in: Investigational New Drugs | Issue 4/2013

Summary

The HGF/MET signaling pathway regulates a wide variety of normal cellular functions that can be subverted to support neoplasia, including cell proliferation, survival, apoptosis, scattering and motility, invasion, and angiogenesis. MET over-expression (with or without gene amplification), aberrant autocrine or paracrine ligand production, and missense MET mutations are mechanisms that lead to activation of the MET pathway in tumors and are associated with poor prognostic outcome. We report here preclinical development of a potent, orally bioavailable, small-molecule inhibitor LY2801653 targeting MET kinase. LY2801653 is a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase with a dissociation constant (K_i) of 2 nM, a pharmacodynamic residence time (K_off) of 0.00132 min⁻¹ and t_1/2 of 525 min. LY2801653 demonstrated in vitro effects on MET pathway-dependent cell scattering and cell proliferation; in vivo anti-tumor effects in MET amplified (MKN45), MET autocrine (U-87MG, and KP4) and MET over-expressed (H441) xenograft models; and in vivo vessel normalization effects. LY2801653 also maintained potency against 13 MET variants, each bearing a single-point mutation. In subsequent nonclinical characterization, LY2801653 was found to have potent activity against several other receptor tyrosine oncokinases including MST1R, FLT3, AXL, MERTK, TEK, ROS1, DDR1/2 and against the serine/threonine kinases MKNK1/2. The potential value of MET and other inhibited targets within a number of malignancies (such as colon, bile ducts, and lung) is discussed. LY2801653 is currently in phase 1 clinical testing in patients with advanced cancer (trial I3O-MC-JSBA, NCT01285037).

Available only for authorised users

Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915–25PubMedCrossRef

Comoglio PM, Giordano A, Trusolino L (2008) Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Disc 7:504–16CrossRef

Turke AB, Zejnullahum K, Wu YL, Song Y, Dias-Santagata D, Lifshits E et al (2010) Preexistence and clonal selection of Met amplification in EGFR mutant NSCLC. Cancer Cell 17:77–88PubMedCrossRef

Yamada T, Takeuchi S, Kita K, Bando H, Nakamura T, Matsumoto K et al (2011) Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer. J Thoracic Oncol 7:272–80CrossRef

Bean J, Brennan C, Shih JY, Riely GJ, Viale A, Wang L et al (2007) Met amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Nat’l Acad Sci USA 104:20932–7CrossRef

Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al (2007) Met amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039–43PubMedCrossRef

Benvenuti S, Lazzari L, Arnesano A, Chiavi GL, Gentile A, Comoglio PM (2011) RON kinase trans-phosphorylation sustains MET oncogene addition. Cancer Res 71:1945–55PubMedCrossRef

Yeh CY, Shih SM, Yeh HH, Wu TJ, Shin JW, Chang TY et al (2011) Transcriptional activation of the Axl and PDGFR-alpha by cMet through a ras- and Src-independent mechanism in human bladder cancer. BMC Cancer 11:139PubMedCrossRef

Li T, Pobanz MA, Shih C, Wu Z, Yang WJ, Zhong B (2011) Amidophenoxyindazoles useful as inhibitors of c-Met. US 8030302B2

10.

Wang W, Marimuthu A, Tsai J, Kumar A, Krupka HI, Zhang C et al (2006) Structural characterization of autoinhibited c-MET kinase produced by coexpression in bacteria with phosphatase. Proc Nat’l Acad Sci USA 103:3563–8CrossRef

11.

Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Cryst Section D D60:2126–32CrossRef

12.

Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Cryst Section D D53:240–55CrossRef

13.

Rong S, Oskarsson M, Faletto D, Tsarfaty I, Resau JH, Nakamura T et al (1993) Tumorigenesis induced by coexpression of human hepatocyte growth factor and the human met protooncogene leads to high levels of expression of the ligand and receptor. Cell Growth Differ 4:563–9PubMed

14.

Park M, Dean M, Kaul K, Braun MJ, Gonda MA, Vande Woude GF (1987) Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc Nat’l Acad Sci USA 84:6379–83CrossRef

15.

Aarts LH, Roovers O, Ward AC, Touw IP (2004) Receptor activation and 2 distinct COOH-terminal motifs control G-CSF receptor distribution and internalization kinetics. Blood 103:571–9PubMedCrossRef

16.

Meier T, Uhlik MT, Chintharlapalli S, Dowless M, Van Horn R, Stewart J et al (2011) Tasisulam sodium, an antitumor agent that inhibits mitotic progression and induces vascular normalization. Mol Cancer Ther 10:2168–78PubMedCrossRef

17.

Underiner TL, Herbertz T, Miknyoczki SJ (2010) Discovery of small molecule c-Met inhibitors: evolution and profiles of clinical candidates. Anti-cancer agents Med Chem 10:7–27CrossRef

18.

Gherardi E, Birchmeier W, Birchmeier C, Vande Woude GF (2012) Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12:89–103PubMedCrossRef

19.

Wang MH, Kurtz AL, Chen YQ (2000) Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells. Carcinogenesis 21:1507–12PubMedCrossRef

20.

Quentmeier H, Reinhardt J, Zaborski M, Drexler HG (2003) Flt3 mutations in acute myeloid leukemia cell lines. Leukemia 17:120–4PubMedCrossRef

21.

Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P et al (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68–73PubMedCrossRef

22.

Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, De Stefani A et al (2000) Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 19:1547–55PubMedCrossRef

23.

Sattler M, Hasina R, Reddy MM, Gangadhar T, Salgia R (2011) The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Ther Adv Med Oncol 3:171–84PubMedCrossRef

24.

Lee CC, Jia Y, Li N, Sun X, Ng K, Ambing E et al (2010) Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. Biochem J 430:425–37PubMedCrossRef

25.

Jauch R, Cho MK, Jakel S, Netter C, Schreiter K, Aicher B et al (2006) Mitogen-activated protein kinases interacting kinases are autoinhibited by a reprogrammed activation segment. EMBO J 25:4020–32PubMedCrossRef

26.

Jauch R, Jäkel S, Netter C, Schreiter K, Aicher B, Jäckle H et al (2005) Crystal structures of the Mnk2 kinase domain reveal an Inhibitory conformation and a zinc binding site. Structure 13:1559–68PubMedCrossRef

27.

Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T et al (2012) Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44:852–60PubMedCrossRef

28.

DaSilva J, Xu L, Kim HJ, Miller WT, Bar-Sagi D (2006) Regulation of sprouty stability by Mnk-1-dependent phosphorylation. Mol Cell Biol 26:1898–907PubMedCrossRef

29.

Ueda T, Sasaki M, Elia AJ, Chio LIC, Hamada K, Fukunaga R et al (2010) Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development. Proc Nat’l Acad Sci USA 107:13984–90CrossRef

30.

El-Deeb IM, Yoo KH, Lee SH (2010) ROS receptor tyrosine kinase: a new potential target for anticancer drugs. Med Res Rev. doi:10.1002/med.20206:1-25

31.

Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H et al (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:1190–203PubMedCrossRef

32.

Gu TL, Deng X, Huang F, Tucker M, Crosby K, Rimkunas V et al (2011) Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 6:e15640PubMedCrossRef

33.

Bergethon K, Shaw AT, Ou SHI, Katayama R, Lovly CM, McDonald NT et al (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863–70PubMedCrossRef

34.

Bai Y, Li J, Fang B, Edwards A, Zhang G, Bui M et al (2012) Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res 72:2501–11PubMedCrossRef

35.

Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W et al (2011) Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Dis 1:78–89CrossRef

36.

Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62PubMedCrossRef

37.

Sengupta S, Gherardi E, Sellers LA, Wood JM, Sasisekharan R, Fan TPD (2003) Hepatocyte growth factor/scatter factor can induce angiogenesis independently of vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 23:69–75PubMedCrossRef

38.

Verma A, Warner SL, Vankayalapati H, Bearss DJ, Sharma S (2011) Targeting Axl and Mer kinases in cancer. Mol Cancer Ther 10:1763–73PubMedCrossRef

39.

Huang H, Bhat A, Woodnutt G, Lappe R (2010) Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 10:575–85PubMedCrossRef

Title: LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models
Authors: S. Betty Yan
Victoria L. Peek
Rose Ajamie
Sean G. Buchanan
Jeremy R. Graff
Steven A. Heidler
Yu-Hua Hui
Karen L. Huss
Bruce W. Konicek
Jason R. Manro
Chuan Shih
Julie A. Stewart
Trent R. Stewart
Stephanie L. Stout
Mark T. Uhlik
Suzane L. Um
Yong Wang
Wenjuan Wu
Lei Yan
Wei J. Yang
Boyu Zhong
Richard A. Walgren
Publication date: 01-08-2013
Publisher: Springer US
Published in: Investigational New Drugs / Issue 4/2013
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-012-9912-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 4/2013

Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer

Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma

Preclinical antitumor activity of a nanoparticulate SN38

Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors

Opioid growth factor (OGF) for hepatoblastoma: a novel non-toxic treatment

Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer